Company ProfilePremium

Cisbio

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cisbio - Healthcare showcase

Year Founded & Workforce

1985

Industry

Healthcare

Services

Biomarkers
C

Cisbio Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cisbio Overview

Company Headquarters: Codolet, France

Founded: 1985

Company Working: Cisbio is a life sciences company involved in the manufacturing of assays and reagents. It offers kits and reagents to address the G protein-coupled receptor activation pathway, cellular protein assays, non-phosphorylated proteins assays, and receptor binding assays, among others. The company provides its products for various therapeutic areas, including cardiovascular, infectious diseases, inflammation/immunology, metabolism/diabetes, neurosciences, oncology, and rare diseases. It has its facilities in France, the US, and China, as well as a network of sales offices and distributors across the globe. As Cisbio operates as a subsidiary of PerkinElmer, Inc., the financials mentioned are of the parent company.

Strategy

Cisbio focuses on developing innovative products by understanding the complexity, diversity, and use of biomarkers. It is actively involved in strategic collaborations to increase its market penetration. Additionally, the company is aiming to expand its distribution network throughout the world.

Company Snapshot

$2,104.8M

Revenue

1985

Founded

Codolet, France

Headquarters

SWOT Analysis

Strengths

  • Actively involved in joint ventures
  • Diverse product portfolio
  • Strong brand name
  • Strong sales and market strategies

Weaknesses

  • Legal disputes
  • Increasing credit risk
  • Legal complications

Opportunities

  • Expansion to developing regions
  • Strategic approach by cutting manufacturing cost

Threats

  • Increasing market competition
  • Strict political and regulatory environment
  • Deviations in legal aspects of regulatory policies in healthcare
  • Price wars

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
–AcquisitionCisbio announced that it had been acquired by PerkinElmer, Inc. which will enable life science, researchers, to have access to assay tools that address a broad diversity of disease types. Through this, the company plans to attract new customers and strengthen its position in the market.
–CollaborationCisbio and Excellerate Bioscience announced its collaboration to deliver ligand kinetic binding assay services. With this, the company aims to establish its position in the market further.

Product Offering

  • Cisbio
    • Biomarkers

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 2,068 Mn in 2016 to USD 2,289 Mn in 2018.
Cisbio — By Business Segment
Series (USD Mn)201620172018
Sales2,0682,1602,289

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.